Innate Pharma wraps up Phase 1 dose-escalation enrollment for IPH4502 ADC; early responses emerge in heavily pre-treated cancers
IPHA sits 45% above its 52-week low of $1.17.
Summary
Innate Pharma has completed enrollment in the Phase 1 dose escalation of its Nectin-4 ADC IPH4502, with early responses seen in heavily pre-treated solid tumors and a clean safety profile. The year-end data readout is a pivotal event for the cash-strapped biotech.
Key Events · Product Development and Regulatory · IPHA
-
Phase 1 Dose Escalation Enrollment Complete
The IPH4502-101 study has enrolled 76 patients across France and the US, evaluating the Nectin-4 ADC in advanced solid tumors.
-
Early Efficacy Signals in Hard-to-Treat Cancers
Objective responses have been observed in heavily pre-treated patients with post-enfortumab vedotin urothelial carcinoma, NSCLC, and HNSCC.
-
Favorable Safety Profile with Limited Hematologic Toxicity
A proprietary linker appears to slow free exatecan release, minimizing bone marrow toxicity—a key differentiator from other ADCs.
-
Year-End 2026 Data Readout as Critical Catalyst
Preliminary data from the full dose escalation cohort are expected by year-end, guiding dose optimization and next development steps.
Analysis · IPHA · Life Sciences
Enrollment is now complete in the dose-escalation portion of the Phase 1 study for IPH4502, a novel Nectin-4 ADC, with 76 patients on board. Early data reveal objective responses in heavily pre-treated patients with post-EV urothelial carcinoma, NSCLC, and HNSCC, alongside a favorable safety profile and limited hematological toxicity. For a company whose cash runway extends only into Q3 2026, this marks a critical de-risking event for its lead wholly-owned asset. Positive results could unlock partnership or financing interest, while the year-end data readout stands as a near-term catalyst that may determine whether the company can continue as a going concern.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IPHA was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162M. The 52-week trading range was $1.17 to $2.63. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.